Grufity logoGrufity logo
StocksFundsSearch FilingsAPI

Repare Therapeutics Inc. Stock Research

RPTX

12.19USD-0.14(-1.14%)Market Closed
Watchlist

Market Summary

USD12.19-0.14
Market Closed
-1.14%

RPTX Stock Price

RPTX RSI Chart

RPTX Valuation

Market Cap

513.1M

Price/Earnings (Trailing)

-166.38

Price/Sales (Trailing)

3.59

EV/EBITDA

19.29

Price/Free Cashflow

-66.67

RPTX Price/Sales (Trailing)

RPTX Profitability

EBT Margin

-7.96%

Return on Equity

-11.63%

Return on Assets

-8.69%

Free Cashflow Yield

-1.5%

RPTX Fundamentals

RPTX Revenue

Revenue Y/Y

-46.44%

Revenue Q/Q

24.87%

RPTX Earnings

Earnings (TTM)

-3.1M

Earnings Y/Y

68.64%

Earnings Q/Q

65.81%

Price Action

52 Week Range

8.0218.68
(Low)(High)

Last 7 days

18.1%

Last 30 days

18.0%

Last 90 days

6.7%

Trailing 12 Months

4.6%

RPTX Financial Health

Current Ratio

4.02

RPTX Investor Care

Shares Dilution (1Y)

0.46%

Diluted EPS (TTM)

-0.15

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales

Latest Insider Trading transactions for RPTX

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-06-08
Zinda Michael
acquired
34,485
12.02
2,869
evp, chief scientific officer
2023-06-07
Zinda Michael
sold
-77,040
12.03
-6,404
evp, chief scientific officer
2023-06-06
Zinda Michael
sold
-14,448
12.04
-1,200
evp, chief scientific officer
2023-01-30
Zinda Michael
acquired
-
-
24,550
evp, chief scientific officer
2023-01-30
Segal Lloyd Mitchell
acquired
-
-
78,550
president and ceo
2023-01-30
Forte Steve
acquired
-
-
24,530
evp, chief financial officer
2023-01-30
Koehler Maria
acquired
-
-
26,450
evp, chief medical officer
2022-12-29
Jerel Davis
acquired
-
-
4,254
-
2022-12-29
Jerel Davis
acquired
-
-
70,678
-
2022-12-20
Koehler Maria
acquired
100,040
2.06238
48,507
evp, chief medical officer

1–10 of 50

Which funds bought or sold RPTX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-09-20
BARCLAYS PLC
new
-
36,000
36,000
-%
2023-09-07
MPM ASSET MANAGEMENT LLC
unchanged
-
1,659,550
23,727,100
11.64%
2023-09-06
Deep Track Capital, LP
unchanged
-
2,018,430
28,858,100
1.34%
2023-08-22
CHI Advisors LLC
added
0.03
2,226,890
31,726,600
9.63%
2023-08-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
added
0.65
13,378
176,220
-%
2023-08-16
Nuveen Asset Management, LLC
sold off
-100
-235,000
-
-%
2023-08-15
LAZARD ASSET MANAGEMENT LLC
added
2.74
3,000
28,000
-%
2023-08-15
GOLDMAN SACHS GROUP INC
reduced
-15.57
-69,898
687,890
-%
2023-08-15
WELLS FARGO & COMPANY/MN
reduced
-2.81
551
12,812
-%
2023-08-14
CITADEL ADVISORS LLC
added
2,122
2,175,730
2,270,760
-%

1–10 of 48

Latest Funds Activity

Are funds buying RPTX calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own RPTX
No. of Funds

Schedule 13G FIlings of Repare Therapeutics

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2023
deep track capital, lp
6.50%
2,727,606
SC 13G/A
Feb 14, 2023
biotechnology value fund l p
10.6%
4,443,423
SC 13G/A
Feb 14, 2023
price t rowe associates inc /md/
0.1%
26,894
SC 13G/A
Feb 14, 2023
redmile group, llc
6.4%
2,684,396
SC 13G/A
Feb 13, 2023
chi advisors llc
6.67%
2,800,126
SC 13G/A
Feb 09, 2023
fmr llc
-
0
SC 13G/A
Jan 06, 2023
versant venture capital v, l.p.
1.3%
563,403
SC 13D/A
Jun 13, 2022
versant venture capital v, l.p.
2.0%
850,560
SC 13D/A
Jun 06, 2022
biotechnology value fund l p
10.4%
4,368,757
SC 13G/A
Feb 14, 2022
redmile group, llc
6.7%
2,789,496
SC 13G/A

Recent SEC filings of Repare Therapeutics

View All Filings
Date Filed Form Type Document
Aug 09, 2023
8-K
Current Report
Aug 09, 2023
10-Q
Quarterly Report

Peers (Alternatives to Repare Therapeutics)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
2.7T
383.9B
-3.49% 14.63%
28.86
7.12
-0.93% -4.89%
2.4T
211.9B
-3.06% 31.92%
32.56
11.12
6.88% -0.52%
1.7T
289.5B
-1.47% 30.51%
27.19
5.72
4.10% -15.36%
1.3T
538.0B
-4.72% 10.07%
101.87
2.47
10.73% 12.62%
MID-CAP
1.5B
9.9B
-28.14% -36.34%
55.75
0.15
24.14% 106.11%
795.7M
246.5M
-4.07% -6.47%
-5.01
3.23
6.65% -174.04%
SMALL-CAP
1.6B
627.1M
-7.75% -14.29%
-1.08
2.51
-0.20% -204.67%
1.5B
2.2B
-10.06% 7.70%
11.01
0.71
38.20% -10.10%
1.0B
543.3M
-3.23% 5.22%
-715.94
1.91
31.74% 78.13%
961.6M
56.2M
-5.30% -69.36%
-1.14
17.12
40.31% -12.26%
614.9M
356.8M
-16.65% -37.31%
-2.19
1.72
-23.03% 15.53%
507.0M
1.0B
-15.90% -35.94%
-19.18
0.49
-11.34% -107.10%
462.3M
453.3M
100.98% -69.12%
-0.38
1.02
-16.04% 55.90%
104.1M
13.7M
-12.49% -77.75%
-0.62
7.62
413.65% 52.51%

Repare Therapeutics News

Nasdaq
Strength Seen in Repare Therapeutics Inc. (RPTX): Can Its 12.2 ....
Nasdaq,
5 days ago
The Motley Fool
Yahoo Finance
10 Oversold Canadian Stocks To Buy.
Yahoo Finance,
51 days ago
Investors Chronicle

Returns for RPTX

Cumulative Returns on RPTX

-28.3%


3-Year Cumulative Returns

Risks for RPTX

What is the probability of a big loss on RPTX?

98.3%


Probability that Repare Therapeutics stock will be more than 20% underwater in next one year

97.1%


Probability that Repare Therapeutics stock will be more than 30% underwater in next one year.

60.2%


Probability that Repare Therapeutics stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does RPTX drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Repare Therapeutics was unfortunately bought at previous high price.

Drawdowns

Financials for Repare Therapeutics

Income Statement (Last 12 Months)
Income Statement (Last 12 Months)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q4
Revenue---131,830,00090,500,66749,171,3337,842,0007,600,000964,000890,000664,000135,000
Operating Expenses2.0%159,842,000156,748,000151,626,000149,407,000142,218,000129,751,000116,260,00097,861,00079,991,00065,368,00054,437,000
  S&GA Expenses2.4%33,091,00032,310,00032,560,00032,260,00030,952,00029,755,00026,213,00023,369,00020,769,00017,400,00014,346,000
  R&D Expenses1.9%126,751,000124,438,000119,066,000117,147,000111,266,00099,996,00090,047,00074,492,00059,222,00047,968,00040,091,000
EBITDA100.0%--6,631,000-9,956,000--131,311,000-119,852,000-106,875,000---63,748,000-54,742,000
EBITDA Margin100.0%--0.05-0.08--15.93-15.28-14.06---96.01-405
Interest Expenses---1,966,000---240,000---216,000
Earnings Before Taxes278.3%18,724,000-10,500,000-13,900,000-25,972,000-133,087,000-121,757,000-108,586,000-96,701,000-78,746,000-63,748,000-54,742,000
EBT Margin100.0%--0.08-0.11-0.29-16.15-15.53-14.29-100-88.48-96.01-405
Net Income89.4%-3,084,000-29,231,000-29,047,000-25,679,000-132,032,000-120,248,000-106,908,000-93,881,000-76,740,000-62,233,000-53,417,000
Net Income Margin100.0%--0.22-0.22-0.28-16.02-15.33-14.07-97.39-86.22-93.72-395
Free Cashflow100.0%--2,048,000-280,0006,734,000-114,255,000-102,980,000-87,486,000-81,251,000-68,731,000-13,573,000-8,321,000
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22019Q4
Assets-10.3%302336364409308337369296321339357370382103
  Current Assets-10.3%29232635439129031935128030932834736137799.00
    Cash Equivalents-4.9%11612116015527630533426129431232634837095.00
  Net PPE-10.7%5.005.004.005.005.005.006.004.004.004.004.003.002.002.00
Liabilities-34.0%56.0085.0085.0010383.0078.0080.0077.0076.0071.0070.0069.0068.0013.00
  Current Liabilities-34.2%53.0081.0079.0062.0039.0034.0035.0023.0023.0012.0011.0010.0010.004.00
Shareholder's Equity-2.3%245251280306226259288218245268287301314-
  Retained Earnings-4.4%-286-274-239-207-283-245-210-181-151-124-103-88.09-74.34-49.94
  Additional Paid-In Capital14.5%49.0043.0037.0032.0027.0023.0018.0014.0011.008.006.005.004.004.00
Shares Outstanding0.0%42.0042.0042.0042.0042.0042.0042.0037.0037.0037.0037.0014.003.002.00
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Last 12 Months)
(In Thousands)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q2
Cashflow From Operations-422.0%-7,611-1,4583229,221-111,710-101,575-85,796-78,005-65,336-10,594-6,084-2,48311,770-33,218-18,429-23,404-6,464
  Share Based Compensation7.2%22,51820,99819,69118,44917,08915,52712,8299,9397,1174,3232,5371,729985795511508372
Cashflow From Investing16.2%-153,208-182,867-175,778-210,234-1,693-501-1,676-10,525-10,609-10,505-9,763-1,259-967-1,272-1,304-724-760
Cashflow From Financing-15.7%8871,05288095,27795,37195,61595,5571,284-774247,803247,842247,553331,496109,960103,243328,99241,990

RPTX Income Statement

2023-06-30
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Revenue:    
Collaboration agreements$ 30,249$ 679$ 35,927$ 1,087
Operating expenses:    
Research and development, net of tax credits33,78831,47565,61857,933
General and administrative8,7197,93817,24816,717
Total operating expenses42,50739,41382,86674,650
Loss from operations(12,258)(38,734)(46,939)(73,563)
Other income (expense), net    
Realized and unrealized (loss) gain on foreign exchange(41)141(97)124
Interest income3,4895446,916673
Other expense(26)(11)(41)(19)
Total other income, net3,4226746,778778
Loss before income taxes(8,836)(38,060)(40,161)(72,785)
Income tax expense(3,110)(33)(6,726)(65)
Net loss(11,946)(38,093)(46,887)(72,850)
Unrealized (loss) gain on available-for-sale marketable securities(189)040
Total other comprehensive (loss) gain(189)040
Comprehensive loss$ (12,135)$ (38,093)$ (46,883)$ (72,850)
Net loss per share attributable to common shareholders--basic$ (0.28)$ (0.91)$ (1.11)$ (1.74)
Net loss per share attributable to common shareholders--diluted$ (0.28)$ (0.91)$ (1.11)$ (1.74)
Weighted-average common shares outstanding-basic42,089,53041,899,50942,065,23741,880,666
Weighted-average common shares outstanding-diluted42,089,53041,899,50942,065,23741,880,666

RPTX Balance Sheet

2023-06-30
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
CURRENT ASSETS:  
Cash and cash equivalents$ 115,544$ 159,521
Marketable securities165,148184,420
Income tax receivable1,7510
Other current receivables5,2814,323
Prepaid expenses4,2015,715
Total current assets291,925353,979
Property and equipment, net4,8214,228
Operating lease right-of-use assets4,4345,371
Other assets408497
TOTAL ASSETS301,588364,075
CURRENT LIABILITIES:  
Accounts payable4,893461
Accrued expenses and other current liabilities21,62821,645
Operating lease liability, current portion2,3202,171
Deferred revenue, current portion24,41253,102
Income tax payable01,240
Total current liabilities53,25378,619
Operating lease liability, net of current portion2,2263,257
Deferred revenue, net of current portion6952,682
TOTAL LIABILITIES56,17484,558
SHAREHOLDERS’ EQUITY  
Preferred shares, no par value per share; unlimited shares authorized as of June 30, 2023 and December 31, 2022, respectively; 0 shares issued and outstanding as of June 30, 2023, and December 31, 2022, respectively00
Common shares, no par value per share; unlimited shares authorized as of June 30, 2023 and December 31, 2022; 42,093,946 and 42,036,193 shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively482,739482,032
Additional paid-in capital49,29937,226
Accumulated other comprehensive loss(424)(428)
Accumulated deficit(286,200)(239,313)
Total shareholders’ equity245,414279,517
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY$ 301,588$ 364,075
Lloyd M. Segal
150
Repare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing RP-6306, which is under Phase I clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta program, a SL target associated with BRCA mutations and other genomic alterations. The company was incorporated in 2016 and is headquartered in Montreal, Canada.